FAQ: Voyageur Pharmaceuticals Distribution Agreement with PHALANX for Mexican Market Expansion

What is the main purpose of this agreement between Voyageur Pharmaceuticals and PHALANX?

The agreement establishes a strategic partnership to drive market expansion of Voyageur’s barium-based contrast media products into the Mexican healthcare sector through PHALANX’s established distribution network.

Why is this partnership significant for Voyageur Pharmaceuticals?

This represents a key milestone in Voyageur’s international growth strategy, expanding the company’s global footprint and supporting access to underserved Latin American markets with increasing demand for high-quality contrast media.

How will the distribution process work under this agreement?

PHALANX will register Voyageur’s barium contrast media products with Mexican health regulatory authorities and distribute them through their established network, with Voyageur providing support for regulatory approval and commercialization efforts.

Who is PHALANX and what expertise do they bring to this partnership?

PHALANX is a leading pharmaceutical distributor based in Mexico with over 20 years of expertise in contrast media for radiology, deep regulatory knowledge, and comprehensive market intelligence for Latin American healthcare markets.

When was this agreement signed and what preceded it?

The agreement was announced on October 29, 2025, following a non-binding Letter of Intent that was announced on June 24, 2025.

Where will Voyageur’s products be distributed under this agreement?

The distribution will focus on the Mexican healthcare sector, with potential expansion to other Latin American countries, subject to local regulatory approvals.

What are the key benefits of this partnership for Voyageur?

The partnership provides access to PHALANX’s established distribution network, regulatory expertise, and market intelligence, accelerating Voyageur’s entry into Latin American markets while minimizing risk.

What regulatory steps are required before products can be sold in Mexico?

PHALANX will lead the registration of Voyageur’s barium contrast media products with Mexican health regulatory authorities, with support from Voyageur’s technical and regulatory team.

Is this an exclusive distribution agreement?

No, this is a non-exclusive distribution and wholesaling agreement, meaning Voyageur can potentially work with other distributors in the region.

What type of products are included in this distribution agreement?

The agreement specifically covers Voyageur’s barium-based contrast media products used in medical imaging procedures.